- Home
- XNCR vs RGNX Comparison
XNCR vs RGNX Comparison
Compare XNCR & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- RGNX
- Stock Information
- Founded
- XNCR 1997
- RGNX 2008
- Country
- XNCR United States
- RGNX United States
- Employees
- XNCR N/A
- RGNX N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XNCR Health Care
- RGNX Health Care
- Exchange
- XNCR Nasdaq
- RGNX Nasdaq
- Market Cap
- XNCR 547.8M
- RGNX 451.1M
- IPO Year
- XNCR 2013
- RGNX 2015
- Fundamental
- Price
- XNCR $8.60
- RGNX $9.20
- Analyst Decision
- XNCR Buy
- RGNX Strong Buy
- Analyst Count
- XNCR 10
- RGNX 8
- Target Price
- XNCR $23.33
- RGNX $28.50
- AVG Volume (30 Days)
- XNCR 700.0K
- RGNX 550.1K
- Earning Date
- XNCR 11-05-2025
- RGNX 11-05-2025
- Dividend Yield
- XNCR N/A
- RGNX N/A
- EPS Growth
- XNCR N/A
- RGNX N/A
- EPS
- XNCR N/A
- RGNX N/A
- Revenue
- XNCR $146,929,000.00
- RGNX $155,782,000.00
- Revenue This Year
- XNCR $22.06
- RGNX $260.25
- Revenue Next Year
- XNCR N/A
- RGNX N/A
- P/E Ratio
- XNCR N/A
- RGNX N/A
- Revenue Growth
- XNCR N/A
- RGNX 74.95
- 52 Week Low
- XNCR $6.92
- RGNX $5.04
- 52 Week High
- XNCR $27.24
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- XNCR 57.89
- RGNX 51.82
- Support Level
- XNCR $8.25
- RGNX $9.35
- Resistance Level
- XNCR $8.73
- RGNX $10.08
- Average True Range (ATR)
- XNCR 0.38
- RGNX 0.53
- MACD
- XNCR 0.07
- RGNX 0.02
- Stochastic Oscillator
- XNCR 78.76
- RGNX 38.46
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.